Denali Therapeutics Inc
(FRA:4DN)
€
20.31
-0.18 (-0.88%)
Market Cap: 2.85 Bil
Enterprise Value: 2.09 Bil
PE Ratio: 0
PB Ratio: 2.25
GF Score: 54/100 Denali Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023 / 05:00PM GMT
Release Date Price:
€25.88
(+3.40%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
Okay. I think we're ready. So good morning, everybody. Thanks for joining us here at the Bank of America Conference in Las Vegas. I'm Tazeen Ahmad. I'm one of the senior SMid biotech analyst here. It's my pleasure to have our next presenting company with me, Denali Therapeutics. Presenting for Denali is CEO, Ryan Watts. So good morning, Ryan.
Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director
Yes. Great to be here. Thank you.
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
So for those who might not be as familiar with the company, maybe just give us a 2-minute overview. There's a lot going on, obviously, but maybe just the top level stuff, and we can go straight into Q&A after that.
Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director
Yes. Great. So definitely a
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot